Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Medtronic
McKinsey
Dow
Boehringer Ingelheim

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Patent: 8,216,997

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,216,997
Title:Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Inventor(s): Seehra; Jasbir (Lexington, MA), Pearsall; Robert Scott (Woburn, MA), Kumar; Ravindra (Acton, MA)
Assignee: Acceleron Pharma, Inc. (Cambridge, MA)
Application Number:12/856,420
Patent Claims:see list of patent claims

Details for Patent 8,216,997

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 010 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 009 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 008 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 007 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 006 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 005 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 004 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,216,997

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKinsey
Merck
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.